Definitive Healthcare Reports 9% Revenue Decline in Q2 2026, Net Loss Improves

Definitive Healthcare Corp. reported a decline in financial performance for the second quarter of 2026, with total revenue of $55.2 million, down 9% from $60.8 million in the same period last year. The decrease was primarily attributed to a drop in subscription revenue, which fell by $5.4 million, while professional services revenue also saw a slight decline. The company experienced a net loss of $7.5 million for the quarter, compared to a loss of $9.3 million in the prior year, indicating a slight improvement in profitability despite the revenue drop.

For the first half of 2026, Definitive Healthcare's revenue totaled $111.1 million, a decrease of 7% from $119.9 million in the first half of 2025. The company reported a significant goodwill impairment charge of $197.2 million during the first quarter, which contributed to a net loss of $199.8 million for the six-month period. This impairment was triggered by declines in the company's market capitalization, necessitating a quantitative assessment of goodwill. The company’s total assets decreased to $496.8 million as of June 30, 2026, down from $735.5 million at the end of 2025.

Operationally, Definitive Healthcare's customer base decreased to approximately 2,200 as of June 30, 2026, down from 2,400 a year earlier. The company reported a net dollar retention rate (NDR) that reflects the percentage of annual recurring revenue retained from existing customers, which is a critical indicator of customer engagement and product adoption. The company has been focusing on expanding its product offerings, including the development of an AI-powered healthcare intelligence platform named Turbo, which is currently in pilot testing with select customers.

In terms of strategic developments, Definitive Healthcare is navigating challenges related to sales execution and macroeconomic conditions that have affected customer spending and retention. The company has implemented a restructuring plan aimed at reducing operating costs, which included a workforce reduction of approximately 40 employees. Additionally, the company received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement for its common stock, which it is actively addressing.

Looking ahead, Definitive Healthcare anticipates continued challenges in revenue growth due to macroeconomic pressures and customer churn, particularly among smaller clients. However, the company is optimistic about the potential for recovery in customer demand and retention as market conditions improve. The management remains focused on leveraging its data analytics capabilities to drive customer engagement and expand its market presence, with a total addressable market estimated at over $11 billion.